@ispor.bsky.social#ISPORNews - Value in Health announced the publication of a new commentary that calls for expanding the role of health economics and outcomes research (#HEOR) and increasing its impact on real-world decision making. Learn more: https://ow.ly/zn9u50ZXYph
@pharmoinstitute.bsky.socialThe countdown is on for the upcoming ISPOR EU 2026! For a full list of our presentations during the ISPOR EU meeting and our colleagues who will be in Vienna, visit: lumanity.com/events/ispor...
@icon-plc.bsky.socialWe're looking forward to sharing new research at #ISPOREurope2026 covering outcomes assessment, regulatory science, systematic reviews, quality-of-life research and AI-enabled methodologies.
Visit ICON at booth #1615.
https://ow.ly/1WOx50ZUkNg
@jme-journal.bsky.social📊 Cell and #genetherapies offer durable, sometimes curative benefits—but high costs mean payers are still catching up on innovative payment and risk-sharing strategies. Elias Pittos & Joe DePinto explore how payers are navigating these challenges. 👇
@journalheor.bsky.socialNew scoping review of 8 rare tumor risk syndromes maps evidence on cancer risk and surveillance, revealing lifetime risks approaching 100% in some syndromes. Still, critical gaps in longitudinal and comparative data hinder cost-effectiveness evaluations. #HEOR #CancerRisk jheor.org/article/167564
@newsen.bsky.socialPetauri Enhances Its Market Access Strategies with Franklin Pharmaceutical Consulting Acquisition #USA #Nashville #Petauri #Franklin_Consulting #HEOR
@ispor.bsky.socialShare your expertise with a global HEOR audience at ISPOR 2027. Submit an abstract for an issue panel, workshop, or other breakout sessions and help shape the leading global conference for #HEOR. Learn more: https://ow.ly/trKH50ZUCux
@journalheor.bsky.socialTargeted literature review across 6 countries finds that lupus nephritis (LN) and membranous nephropathy carry substantial burdens, with high progression to end-stage kidney disease and costs, but significant data gaps limit comprehensive understanding. #HEOR #nephropathy jheor.org/article/166255
@ispor.bsky.socialPlenary Sessions Announced for #ISPOREurope!
Explore thought-provoking discussions on #healthcare policy, #HEOR in decision making, and methodology. See what’s planned: https://ow.ly/fh8S50ZTXCo
@tandfresearch.bsky.socialShaping healthcare’s future through science and policy. Join global leaders at #ISPOREurope2026!
🗓️ 8-11 Nov
📍 Vienna, Austria.
3 days of innovation, 3000+ research abstracts, AI & RWE insights.
Register: spr.ly/6009BG5wyX
@ispor.bsky.social#ISPORNews - ISPOR announced details for #ISPOREurope 2026. The conference is scheduled for 8-11 November in Vienna, Austria with the theme, “Shaping the Future of Access Through Science and Policy.” #HEOR https://ow.ly/a8RQ50ZT0PP
@ispor.bsky.socialEarly registration savings end TOMORROW, 1 October! Join the global #HEOR community at #ISPOREurope for expert panels, research presentations, engaging sessions, and networking. Register now to save: https://ow.ly/Etiy50ZSieU
@ispor.bsky.socialNominations are open for ISPOR’s 2027 HEOR Awards! Know someone who has demonstrated excellence, leadership, or outstanding technical advancement in #HEOR? Recognize exceptional contributions to the field by submitting a nomination. Learn more and submit >> https://ow.ly/QS3N50ZR81K
@journalheor.bsky.socialNew study by Harms et al finds that balloon spacers for rotator cuff tears offer a cost-effective, lower-complication alternative to major surgeries like reverse shoulder arthroplasty, with faster recovery and significantly reduced costs (€3502 vs €9969). jheor.org/article/164920 #HEOR #Arthroplasty
@jme-journal.bsky.socialNew paper tackles a key challenge in #healtheconomics: evaluating diagnostics & medical devices with limited comparative data. The authors use #bladdercancer diagnostics as a case study to demonstrate novel methodological approaches.
Read the article in full here 👉 bit.ly/3TJy9ck
@journalheor.bsky.socialNew study by Rice and colleagues evaluates the cost-effectiveness of extracorporeal photopheresis for chronic lung allograft dysfunction, finding ICERs between £33,343–£88,278/QALY, with potential to qualify for higher thresholds as a specialized treatment. jheor.org/article/1634... #ECP #HEOR
@ispor.bsky.socialISPOR launches new HEOR Ambassadors site that features global thought leaders in health economics and outcomes research. (#HEOR). #ISPORnews #healthcare #speakersbureau
https://ow.ly/9f5U50ZFErs
@yhec.bsky.social🎉 Celebrating 40 years of YHEC: inspiring the next generation of health economists. In our latest blog, we explore how our summer work experience placements help students put their learning into practice and develop new skills.
🔗 Read the blog: www.yhec.co.uk/resource/msc...
@ispor.bsky.socialShare your #HEOR expertise and help shape ISPOR's educational programming. Submit a course proposal on #healthequity, #wholehealth, #AI in HEOR, #digitalhealth, and more.
Deadline: November 2
Submit your proposal >> https://ow.ly/hjoM50ZOlSy
@4040rec.bsky.social